Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug ease long COVID fatigue?

NCT ID NCT07128082

Symptom relief Sponsor: Scripps Translational Science Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether tirzepatide (Zepbound), a drug used for diabetes and weight loss, can reduce Long COVID symptoms like fatigue. About 1000 adults with Long COVID will take either the drug or a placebo for 12 months, and all tasks are done remotely. The main goal is to see if fatigue scores improve compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tirzepatide (Zepbound)
What this could lead to
If it works, this could point toward a treatment that reduces fatigue and improves quality of life for people with Long COVID.
What could go wrong
This is a Phase 2 trial, so it is still early. The medication may not work better than a placebo, and side effects from tirzepatide (like nausea or digestive issues) are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

1,000 people

The number who actually took part.

Started

Oct 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age or older Living in the United States Able to read and understand English or Spanish Willing and able to participate in study interventions and activities, including; * Access to an internet connected device * Informed Consent * Surveys * Medication schedule * Adverse Event reporting * Weight reporting * Use of wearable activity tracker * Completing at home blood collections, if selected Meets the NASEM definition of Long COVID: an infection-associated chronic condition that occurs after SARS-CoV-2 infection and is present for at least 3 months as a continuous, relapsing and remitting, or progressive disease state that affects one or more organ systems 16. Ability to verify identity Ability to verify diagnosis Agree to notify the study team if you start any other Long COVID treatments while enrolled in the study. Complete the Fatigue Severity Scale with a minimum score of 36 Exclusion Criteria: * Certain vulnerable populations (prisoners, children, fetuses, and institutionalized individuals) * Women who are pregnant, excluded due to unknown risks to a fetus * Personal or family history of medullary thyroid carcinoma * History of severe gastrointestinal disease * Diagnosis of gastroparesis * Worsening or chronic renal failure * History of pancreatitis * Multiple Endocrine Neoplasia syndrome type 2 * Known serious hypersensitivity to tirzepatide * Already taking tirzepatide or another GLP-1 agonist * Medication contraindications to tirzepatide * History of suicidal attempts and/or active suicidal ideation * Underweight (BMI under 18.5) * Planning to undergo elective surgery or procedures requiring general anesthesia or deep sedation in the next 12 months * Symptoms of fatigue and/or brain fog that predated infection with COVID-19

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Long COVID are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Long COVID

Contacts and locations

Locations

  • Scripps Research

    La Jolla, California, 92037, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.